Skip to main content

Roche’s Virtual Event following Angiogenesis 2022

Roche has hosted a virtual event on Monday, 14 February 2021.

agenda
Agenda
WelcomeBruno Eschli, Head of Investor Relations
Ophthalmology franchise strategyNilesh Mehta, Global Franchise Head, Ophthalmology
Ophthalmology clinical developmentChristopher Brittain, Vice President and Global Head of Ophthalmology Product Development
Angiogenesis highlights2-Year data for Susvimo in nAMD (Ph III Archway), 2-Year data for Vabysmo in DME (Ph III YOSEMITE & RHINE), Nancy Holekamp, M.D., Retina Specialist
Q&A

Webinar Replay

InvestorsPast IR Events
View more Events

Downloads

Download Presentation

PDF

Discover more

  • Governance

    About Roche

    Our corporate governance principles focus on sustainable value creation and promote a culture that recognises standards of good corporate governance and a commitment to transparent communication.

  • Product Development Pipeline

    Solutions

    Discover our pipeline of Pharmaceutical and Diagnostics developments

  • Frequently asked questions

    Investors

    We answer the Roche investors-related most frequently asked questions

  • Finance Information Tool

    Investors

    Access the finance information tool for the latest Roche financial data.